About Pegaspargase 750U/ml
Pegylated enzyme antineoplastic
Used for
- Used with other medicines to treat acute lymphoblastic leukaemia (ALL).
Usual adult dose
Usually 2,000 IU/m² by injection or infusion every 14 days; dosing depends on treatment protocol.
Usual dose in children
Usually 2,500 IU/m² every 14 days for children under 21; dosing depends on treatment protocol.
Common side effects
- Allergic reactions, including severe reactions
- Pancreatitis
- Blood clots or bleeding problems
- Liver problems, nausea, or raised blood sugar
Important warnings
- Can cause severe allergy, pancreatitis, liver injury, blood clots, or bleeding.
- Monitoring of blood counts, liver function, blood clotting, and pancreatic enzymes is needed.
- Use only under specialist supervision as part of a leukaemia treatment protocol.
Pregnancy
May harm an unborn baby. Pregnancy prevention is needed during treatment and for at least six months afterwards.
Breastfeeding
Breastfeeding is not recommended during treatment and for at least one month after the last dose.
Interactions
- Other chemotherapy medicines can increase liver, clotting, or pancreas-related risks.
- Live vaccines should generally be avoided during chemotherapy.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.